+44 20 8123 2220
info@marketpublishers.com

Soft Tissue Sarcoma - Pipeline Insight, 2021

https://marketpublishers.com/r/SB4C2AD3858EN.html
Date: July 2021
Pages: 248
Price: US$ 3,000.00 (Single User License)
ID: SB4C2AD3858EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Soft Tissue Sarcoma - Pipeline Insight, 2021," report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Soft Tissue Sarcoma Understanding

Soft Tissue Sarcoma: Overview

Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease's clinical course. According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected

+44 20 8123 2220
info@marketpublishers.com

individuals may notice slow-growing, painless mass in the affected area.

'Soft Tissue Sarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided which includes the disease overview and Soft Tissue Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Soft Tissue Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Soft Tissue Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Soft Tissue Sarcoma.

Soft Tissue Sarcoma Emerging Drugs Chapters

This segment of the Soft Tissue Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Soft Tissue Sarcoma Emerging Drugs

AL3818: Advenchen Laboratories

AL3818 is a novel small molecule dual receptor tyrosine kinase inhibitor, which shows highly selective inhibition of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR). Advenchen Laboratories, LLC is developing AL-3818 for the treatment of patients with advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), synovial sarcoma (SS), and soft-tissue

+44 20 8123 2220
info@marketpublishers.com

sarcoma (STS). The drug is currently in the Phase III stage of development.

L19 TNF: Philogen

Onfekafusp alfa (L19 TNF) is a fully human recombinant fusion protein being developed by Philogen for the treatment of cancer, including gliomas, glioblastoma. It is a human antibody-cytokine fusion protein consisting of the non-covalent trimer of tumor necrosis factor (TNF) fused to an antibody specific to the extra-domain B of fibronectin (L19) in the single-chain variable fragment (scFv) format. The antibody-TNF fusion protein selectively localizes to tumor lesions following systemic administration. It is currently being studied in Phase III and Phase II of clinical development to treat STS patients in Europe and the United States, respectively.

NBTXR3: Nanobiotix

Hensify (NBTXR3), is a first-in-class nanoparticle radio-enhancer designed for direct injection into cancerous tumors and is engineered to increase the dose and efficacy of radiotherapy without increasing toxicity or causing damage to surrounding healthy tissues. NBTXR3 has the potential to improve radiotherapy efficacy by destroying locally advanced tumors more efficiently, improving the chance of full tumor resection. Treatment with NBTXR3 nanoparticles and radiotherapy in locally advanced STS aims to destroy tumors more efficiently, to facilitate surgery and enable complete malignant tissue extraction during surgery. Currently, it is in phase II/III stage of development.

GPX-150: Monopar Therapeutics

GPX-150, also known as camsirubicin, is a novel proprietary analog of the widely used cancer drug doxorubicin. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. The drug is currently being studied in the Phase II stage of development for the treatment of patients with STS.

LTX-315: Lytix Biopharma

Lytix’s product candidate LTX-315 is a first-in-class oncolytic peptide with the potential

+44 20 8123 2220
info@marketpublishers.com

to fully personalize immunotherapy. LTX-315 is developed for the intratumoral treatment of solid tumors turning cold tumors hot. LTX-315 triggers the immune system to recognize, infiltrate and attack the cancer cells, opening up the tumor for various combination treatments, including the marketed checkpoint inhibitors.

Nivolumab: Bristol Myers Squibb

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). PD-L1 and PD-L2 ligands bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2 ligands on their surface. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response. The clinical trials for nivolumab are currently ongoing in phase II for the treatment of patients with STS.

Lenvatinib: Merck sharp & Dohme Corp.

Lenvatinib is an orally available, multiple receptor tyrosine kinase (RTK) inhibitor with the novel binding mode that selectively inhibits the kinase activities of VEGFR-1, -2, and -3. The drug is currently being studied in Phase II in combination with pembrolizumab, a monoclonal antibody that binds to PD-1 and prevents its interaction with PD-1 and PD-2.

Durvalumab: AstraZeneca

Durvalumab is a human immunoglobulin G1 kappa (IgG1?) monoclonal antibody and a novel immune checkpoint inhibitor for cancer treatment. The expression of PD-L1 is an adaptive immune response by tumor cells, resulting in overexpression of the molecule in some cancers. Durvalumab activates the immune responses mediated by cytotoxic T-cells that attack tumor cells by binding to PD-L1, thereby inhibiting its interaction with PD-1 on T-cells. The drug is currently in Phase II clinical trial for the treatment of patients with metastatic STS.

Nintedanib: Boehringer Ingelheim

+44 20 8123 2220
info@marketpublishers.com

Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) ? and ?, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, colony-stimulating factor 1 receptor (CSF1R), and Fms-like tyrosine kinase-3 (FLT-3). These kinases, except for FLT-3 have been implicated in the pathogenesis of interstitial lung diseases (ILD). Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these kinases and blocks the intracellular signaling cascades, which have been demonstrated to be involved in the pathogenesis of fibrotic tissue remodeling in ILD. Nintedanib also inhibits the following nRTKs: Lck, Lyn and Src kinases. The contribution of FLT-3 and nRTK inhibition to nintedanib efficacy in ILD is unknown. Currently, it is in phase 2 stage of development to treat soft tissue sarcoma.

Further product details are provided in the report……..

Soft Tissue Sarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Soft Tissue Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Soft Tissue Sarcoma

There are approx. 130+ key companies which are developing the therapies for Soft Tissue Sarcoma. The companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Philogen.

Phases

DelveInsight’s report covers around 130+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

+44 20 8123 2220
info@marketpublishers.com

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intra-arterial

Intradermal

Intralesional

Intratumoral

Intravenous

Oral

Parenteral

Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

Antibody

Antibody–drug conjugate

+44 20 8123 2220
info@marketpublishers.com

- Cell therapy
- Gene therapy
- Immunotherapy
- Nanoparticle
- Peptide
- Recombinant fusion protein
- Small molecule
- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Soft Tissue Sarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Soft Tissue Sarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Soft Tissue Sarcoma drugs.

Soft Tissue Sarcoma Report Insights

- Soft Tissue Sarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs

+44 20 8123 2220
info@marketpublishers.com

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Soft Tissue Sarcoma drugs?

How many Soft Tissue Sarcoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Soft Tissue Sarcoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Soft Tissue Sarcoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Soft Tissue Sarcoma and their status?

What are the key designations that have been granted to the emerging drugs?

+44 20 8123 2220
info@marketpublishers.com

Key Players

- Advenchen Laboratories
- Philogen
- Gradalis
- Epizyme
- Eli Lilly and Company
- Chugai Pharma France
- CytRx
- AROG Pharmaceuticals
- Taiho Pharmaceuticals
- NantCell
- KaryoPharm Therapeutics
- Nanobiotix
- Apexigen
- Gem Pharmaceuticals
- Lytix Biopharma
- Novartis
- Athenex
- Bristol Myers Squibb
- Merck Sharp & Dohme

+44 20 8123 2220
info@marketpublishers.com

Bristol Myers Squibb

Incyte Corporation

Daiichi Sankyo

AstraZeneca

Pfizer

Merck Sharp & Dohme

NantPharma

Iovance Biotherapeutics

Agenus

Eli Lilly and company

AstraZeneca

Adaptimmune

Aadi

Jiangsu HengRui Medicine

Bayer

Merck

GlaxoSmithKline

AVEO Pharmaceuticals

Amgen

+44 20 8123 2220
info@marketpublishers.com

Atara Biotherapeutics

Roche

Bayer

VasGene Therapeutics

Mirati Therapeutics

EMD Serono

AGC Biologics

Novartis

Genor Biopharma

Clovis Oncology

PharmaMar

Boehringer Ingelheim

Morphotek (Eisai)

GlaxoSmithKline

Novartis

Incyte Corporation

Tracon Pharmaceuticals

Jiangsu Hengrui Medicine

Exelixis

Sanofi

+44 20 8123 2220
info@marketpublishers.com

Pfizer

Merck KGaA

Roche Pharma AG

Bristol-Myers Squibb

Bristol-Myers Squibb

MedImmune

Qbiotics

AstraZeneca

Novartis

AstraZeneca

Aadi

Loxo Oncology

Key Products

AL-3818

Onfekafusp alfa

Vigil

Tazemetostat

Olaratumab

Doxorubicin

+44 20 8123 2220
info@marketpublishers.com

Aldoxorubicin

Crenolanib

TAS-116

Ganitumab

Selinexor

NBTXR3

APX005M

GPX-150

LTX-315

PDR001

Oraxol

Nivolumab

Lenvatinib

Ipilimumab

INCMGA00012

Efatutazone

Durvalumab

Crizotinib

MK3475

+44 20 8123 2220
info@marketpublishers.com

AMG337

LN-145-S1

AGEN2034

Abemaciclib

Olaparib + Trabectedin

ADP-A2M4

ABI-009

Apatinib Mesylate

Sorafenib Tosylate

Temozolomide

TSR-042

Tivozanib

Talimogene laherparepvec

Tabelecleucel

Bevacizumab

Regorafenib

sEphB4-HAS

Sitravatinib

M6620

NGR-hTNF

+44 20 8123 2220
info@marketpublishers.com

Letrozole

GB226

Rucaparib

PM01183

Nintedanib

MORAb-004

NY-ESO-1????T Cells

Everolimus

Epacadostat

Envafolimab

Camrelizumab

cabozantinib

Cabazitaxel

Axitinib

Avelumab

Atezolizumab

Relatlimab

Dasatinib

Tremelimumab

+44 20 8123 2220
info@marketpublishers.com

Tigilanol tiglate

Selumetinib

Gemcitabine

Cediranib

Nab-rapamycin

LOXO- 292

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Soft Tissue Sarcoma - Pipeline Insight, 2021
Product link: https://marketpublishers.com/r/SB4C2AD3858EN.html
Price: US$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/SB4C2AD3858EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970